Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF TECHNICAL OFFICER | February 25, 2025 | February 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,756 |
Ending reported balance
After 2025-02-27 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.
F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 18, 2023 Filed Jul 19, 2023 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,825 | $8.11 | $22,910.75 |
DisclosureSEC source: 0001415889-23-011318 · form4-07192023_080758.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Represents an acquisition of 2,825 shares by the Reporting Person pursuant to a cash exercise and hold transaction. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,175 | $13.81 | $99,086.75 |
DisclosureSEC source: 0001415889-23-011318 · form4-07192023_080758.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents an acquisition of 7,175 shares by the Reporting Person pursuant to a cash exercise and hold transaction. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $40.43 | $404,300.00 |
DisclosureSEC source: 0001415889-23-011318 · form4-07192023_080758.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,911 F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.10 to $40.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $18.41 | $184,100.00 |
DisclosureSEC source: 0001415889-23-011318 · form4-07192023_080758.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 22:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001415889-23-010180 · form4-06222023_100619.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,505 Underlying: Common Stock · 10,000 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 22:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $36.00 | $360,000.00 |
DisclosureSEC source: 0001415889-23-010180 · form4-06222023_100619.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,911 F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 22:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $18.41 | $184,100.00 |
DisclosureSEC source: 0001415889-23-010180 · form4-06222023_100619.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 22:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001415889-23-006740 · form4-04192023_100426.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,505 Underlying: Common Stock · 10,000 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 22:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $36.00 | $360,000.00 |
DisclosureSEC source: 0001415889-23-006740 · form4-04192023_100426.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,911 F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 22:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $18.41 | $184,100.00 |
DisclosureSEC source: 0001415889-23-006740 · form4-04192023_100426.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,984 | $49.55 | $147,854.22 |
DisclosureSEC source: 0001415889-23-003487 · form4-02282023_090212.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,927 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.36 to $49.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 7,016 | $49.55 | $347,628.77 |
DisclosureSEC source: 0001415889-23-003487 · form4-02282023_090212.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,911 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.34 to $49.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2023 Filed Apr 19, 2023 22:01 UTC Amendment | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,984 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001415889-23-006738 · form4a-04192023_100445.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,505 Underlying: Common Stock · 2,984 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| February 27, 2023 Filed Apr 19, 2023 22:01 UTC Amendment | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,984 | $49.55 | $147,854.22 |
DisclosureSEC source: 0001415889-23-006738 · form4a-04192023_100445.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,911 F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.36 to $49.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2 · balance_after: This amendment is being filed to include the option exercise information in Tables I and II and to update the information in Table I, Column 5. Read SEC document |
| February 27, 2023 Filed Apr 19, 2023 22:01 UTC Amendment | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,984 | $18.41 | $54,935.44 |
DisclosureSEC source: 0001415889-23-006738 · form4a-04192023_100445.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · kind: This amendment is being filed to include the option exercise information in Tables I and II and to update the information in Table I, Column 5. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 17,053 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002956 · form4-02222023_120249.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,053 Underlying: Common Stock · 17,053 shares Expires not disclosed F4 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F4 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 48,849 | $0.00 Strike: $49.26 | $0.00 |
DisclosureSEC source: 0001415889-23-002956 · form4-02222023_120249.xml · derivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,849 Underlying: Common Stock · 48,849 shares Expires 2033-02-16 F3 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,112 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002956 · form4-02222023_120249.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,336 Underlying: Common Stock · 6,112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,878 | $49.26 | $141,770.28 |
DisclosureSEC source: 0001415889-23-002956 · form4-02222023_120249.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,927 F1 · shares: The reported disposition of 2,878 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002956 · form4-02222023_120249.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 11:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 3,386 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002714 · form4-02172023_110255.xml · derivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,772 Underlying: Common Stock · 3,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 11:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,170 | $49.20 | $57,564.00 |
DisclosureSEC source: 0001415889-23-002714 · form4-02172023_110255.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,693 F2 · shares: The reported disposition of 1,170 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 11:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 3,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002714 · form4-02172023_110255.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 11:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $48.39 | $483,940.00 |
DisclosureSEC source: 0001415889-23-002714 · form4-02172023_110255.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,477 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 12, 2023 Filed Feb 14, 2023 22:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Unit · Derivative | 7,883 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002515 · form4-02142023_100215.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2023 Filed Feb 14, 2023 22:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,725 | $48.92 | $133,307.00 |
DisclosureSEC source: 0001415889-23-002515 · form4-02142023_100215.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,477 F2 · shares: The reported disposition of 2,725 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2023 Filed Feb 14, 2023 22:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002515 · form4-02142023_100215.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 8,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002515 · form4-02142023_100215.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,133 Underlying: Common Stock · 8,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,951 | $48.92 | $144,362.92 |
DisclosureSEC source: 0001415889-23-002515 · form4-02142023_100215.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,319 F1 · shares: The reported disposition of 2,951 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002515 · form4-02142023_100215.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,122 | $50.93 | $57,138.97 |
DisclosureSEC source: 0001415889-23-001128 · form4-01192023_120143.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,137 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $50.881 to $50.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 8,878 | $50.40 | $447,451.20 |
DisclosureSEC source: 0001415889-23-001128 · form4-01192023_120143.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,259 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.89 to $50.85. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 13, 2022 Filed Dec 13, 2022 23:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 5,065 | $58.66 | $297,133.16 |
DisclosureSEC source: 0001415889-22-012510 · form4-12132022_111228.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,137 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.233 to $59.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 13, 2022 Filed Dec 13, 2022 23:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,935 | $58.67 | $289,541.39 |
DisclosureSEC source: 0001415889-22-012510 · form4-12132022_111228.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,202 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.233 to $59.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 3,115 | $54.14 | $168,642.99 |
DisclosureSEC source: 0001415889-22-011453 · form4-11172022_121133.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,137 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $53.59 to $54.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 8 | $54.61 | $436.88 |
DisclosureSEC source: 0001415889-22-011453 · form4-11172022_121133.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,252 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 6,877 | $54.12 | $372,183.24 |
DisclosureSEC source: 0001415889-22-011453 · form4-11172022_121133.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,260 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $53.59 to $54.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 24,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001394 · edgar.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,448 Underlying: Common Stock · 24,448 shares Expires not disclosed F4 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter. F4 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 74,777 | $0.00 Strike: $34.36 | $0.00 |
DisclosureSEC source: 0001179110-22-001394 · edgar.xml · derivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,777 Underlying: Common Stock · 74,777 shares Expires 2032-02-16 F3 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 3,386 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001394 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,158 Underlying: Common Stock · 3,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,170 | $34.43 | $40,283.10 |
DisclosureSEC source: 0001179110-22-001394 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,137 F1 · shares: The reported disposition of 1,170 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 3,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001394 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,771 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · derivative · entry 9 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,995 | $33.64 | $67,111.80 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · nonDerivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,921 F3 · shares: The reported disposition of 1,995 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,883 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · derivative · entry 8 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,883 Underlying: Common Stock · 7,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,725 | $34.20 | $93,195.00 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,145 F2 · shares: The reported disposition of 2,725 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 8,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,266 Underlying: Common Stock · 8,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,992 | $34.94 | $104,540.48 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,987 F1 · shares: The reported disposition of 2,992 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.